Zenas BioPharma Cash Flow Statement
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.26+1.02 (+3.89%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma free cash flow
In fiscal 2025, Zenas BioPharma generated -$172.3 million of operating cash flow and spent $18,000 on capital expenditures. That left free cash flow of -$172.4 million, a free-cash-flow margin of -1723.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Zenas BioPharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -377.74M | -156.99M | -37.12M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 56.00K | 137.00K | 113.00K |
| Stock-Based Compensation | 26.35M | 10.82M | 3.50M |
| Change in Working Capital | 1.85M | 26.10M | -7.33M |
| Operating Cash Flow | -172.33M | -119.67M | -30.53M |
| Capital Expenditures | -18.00K | -131.00K | -17.00K |
| Investing Cash Flow | -251.89M | -30.55M | -17.00K |
| Debt Issued | 75.00M | — | — |
| Financing Cash Flow | 215.28M | 412.96M | 20.12M |
| Net Change in Cash | -209.19M | 262.89M | -10.35M |
| Free Cash Flow | -172.35M | -119.81M | -30.55M |
This table shows 3 annual periods of Zenas BioPharma's cash flow statement, from FY 2025 back to FY 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ZBIO's reporting calendar. What is a cash flow statement?